The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

Lepu Medical Technology (300003.SZ) plans to invest no more than 0.2 billion yuan to participate in the establishment of a healthcare industry merger and acquisition Fund in Suzhou.

Lepu Medical Technology (300003.SZ) announced that the company has cooperated with the professional investment institution Suzhou Lepu Suwing Consulting Partnership (has...

Zhitong FinanceDec 31, 2024 19:51

Express News | Lepu Medical Technology: Established an investment partnership with professional investment institutions.

BreakingsDec 31, 2024 19:46

Shengnuo Biotechnology (688117.SH): Lepu Medical Technology has cumulatively reduced its shareholding by 0.7912%.

On December 26, Gelonghui reported that Shengnuo Biology (688117.SH) announced that the company recently received a notification letter from Lepu Medical Technology regarding the results of shareholding reduction. As of the date of this announcement, Lepu Medical Technology has cumulatively reduced its shareholding by 889,445 shares through centralized bidding, accounting for 0.7912% of the company's total share capital. After the reduction, Lepu Medical Technology holds 5,272,000 shares of the company, accounting for 4.6896% of the company's total share capital, and this shareholding reduction plan has reached its expiration.

Gelonghui FinanceDec 26, 2024 16:46

Express News | Lepu Medical Technology: Transcatheter implantable aortic valve system has obtained NMPA registration approval.

BreakingsDec 17, 2024 18:35

Lepu Biopharma Renews Procurement Contract With Controlling Shareholder

MT NewswiresNov 27, 2024 17:14